



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/534,345	05/09/2005	Els Beirnaert	A0848.70007US00	4825
23628	7590	05/12/2008		
WOLF GREENFIELD & SACKS, P.C. 600 ATLANTIC AVENUE BOSTON, MA 02210-2206			EXAMINER	
			SKELDING, ZACHARY S	
ART UNIT		PAPER NUMBER		
1644				
MAIL DATE		DELIVERY MODE		
05/12/2008		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10534345	5/9/2005	BEIRNAERT, ELS	A0848.70007US00
EXAMINER			
ZACHARY SKELDING			
ART UNIT	PAPER		
1644	080502		

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner for Patents**

Applicant's provision of a sequence listing, CRF, and statement verifying that the same information is provided in each filed December 13, 2007 is acknowledged.

However, it is noted that the "notification to comply with requirements for patent applications containing nucleotide and/or amino acid sequence disclosures" mailed October 1, 2007 states in the comment sheet that "pages 48, 56 and 58, 1st paragraph on each, of the instant specification contain sequences that fall under the definition of sequences that must be listed in a sequence listings and require a "SEQ ID NO: " appended thereto. See 37 CFR 1.821-1.825... Appropriate correction is required..."

Applicant is required to annotate the sequences disclosed on pages 48, 56 and 58, 1st paragraph on each, of the instant specification as required by 37 CFR 1.821-1.825 and the comment sheet mailed in connection with the notification to comply with requirements for patent applications containing nucleotide and/or amino acid sequence disclosures mailed October 1, 2007.

Since the submission appears to be a bona fide attempt to provide a complete reply to the, applicant is given a shortened statutory period of ONE MONTH or THIRTY DAYS from the mailing date of this letter, whichever is longer, to submit a complete reply. This shortened statutory period supersedes the time period set in the prior Office action. This time period may be extended pursuant to 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ZACHARY SKELDING whose telephone number is (571)272-9033. The examiner can normally be reached on Monday - Friday 8:00 a.m. - 5:00 p.m. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eileen O'Hara can be reached on 571-272-0878. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Zachary Skelding, Ph.D.

Patent Examiner

May 2, 2008

/Mikhail A Belyavskyi/  
Primary Examiner, Art Unit 1644